Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next Generation Sequencing Facilitates Quantitative Analysis of tumor samples from HCC patients receiving Nivolumab.

ABSTRACT: Next Generation Sequencing Facilitates Quantitative Analysis of tumor samples from HCC patients receiving Nivolumab.

PROVIDER: PRJNA906102 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21837788_1.fastq.gz	Fastqsanger.gz
	SRR21837788_2.fastq.gz	Fastqsanger.gz
	SRR21837789_1.fastq.gz	Fastqsanger.gz
	SRR21837789_2.fastq.gz	Fastqsanger.gz
	SRR21837790_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Next Generation Sequencing Facilitates Quantitative Analysis of tumor samples from HCC patients receiving Nivolumab.

Project description:To identify critical tumor-secreting factors that may contribute to immunotherapy efficacy against HCC, we subjected tumor samples from 10 HCC patients to whole-transcriptome sequencing, and categorized the patients into two groups according to clinical response to nivolumab. We then performed gene expression profiling analysis using data obtained from RNA-seq of Nivolumab reponders and non-reponsers.

2023-12-06 | GSE215011 | GEO

Expression data from patients with HCC receiving Nivolumab

Project description:We have generated an immune classifier able to identify patients belonging to the immune subclass of HCC. Characteristics of the immune subclass resemble those of patients who most respond to immunotherapy. We performed microarray expression of the tumors of two patients before starting treatment with nivolumab to verify if the immune classifier generated was able to predict response to immunotherapy.

2018-01-31 | GSE93647 | GEO

Tumor samples from HCC patients receiving Nivolumab THP-1 cells under different stimulas.

Project description:Tumor samples from HCC patients receiving Nivolumab THP-1 cells under different stimulas.

| PRJNA890644 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of DSS-induced colitis receiving Sulfasalazine and Berberine colonrectum Transcriptomes

Project description:We had one goal to perform this study: DSS-induced colitis receiving Sulfasalazine and Berberine colonrectum Transcriptomes

2022-10-31 | GSE216260 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of HCC cells transfected with NCsiRNA or CDCA8siRNA

Project description:We hypothesized if targeting of CDCA8 with small interfering (si) RNA could inhibit HCC progression. We also investigated molecular mechanism to mediate HCC cell death caused by CDCA8 silencing. To accomplish this, Huh1 and Huh7 human HCC cells were transfected with CDCA8 siRNA and tested for growth inhibition and apoptotic induction using MTS, FACS and microscopic analysis. To obtain insights into the molecular changes in response to CDCA8 knockdown, global changes in gene expression were examined using RNA sequencing. As results, siRNA silencing of CDCA8 inhibited HCC cell growth by blocking cell-cycle progression and inducing apoptosis. RNA sequencing showed that, representatively, the anti-proliferative effects were driven by a subset of molecular alterations including the upregulation of tumor suppressive ATF3 and GADD34 genes, whereas a key regulator of cell growth and invasiveness BGLAP was repressed. Subsequent Western blotting also revealed that CDCA8 silencing decreases the levels of pro-caspase 3 and PARP-1, accelerating apoptotic signaling in HCC cells. In addition, targeting CDCA8 effectively suppressed HCC tumor growth growth in a murine xenograft model. Taken together, these findings suggest that CDCA8 could be a promising molecular target for systemic therapy of HCC.

2017-02-14 | GSE77992 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of HCC cells transfected with NCsiRNA or ODC1siRNA

Project description:We investigated if targeting of ODC1 with siRNA could inhibit HCC progression. To accomplish this, Huh1 and Huh7 human HCC cells were transfected with ODC1 siRNA and tested for growth inhibition and apoptotic induction using MTS, FACS and microscopic analysis. To obtain insights into the molecular changes in response to ODC1 knockdown, global changes in gene expression were examined using RNA sequencing. Our results show that ODC1 silencing caused inhibition of HCC cell growth through blockade of cell cycle progression and a strong induction of apoptosis. Subsequent Western blotting revealed that ODC1 silencing decreased the levels of cell cycle regulator cyclin E1, PARP-1, and pro-caspase 3 accelerating apoptotic signaling in HCC cells. In addition, ODC1 silencing resulted in a strong inhibition in the expressions of important regulators of glycolysis and lipogenesis, GLUT4 and ChREBP, and caused a marked decrease in fat accumulation. These findings suggest that ODC1 can be a promising target for systemic therapy of HCC by modulating tumor metabolism.

2016-12-31 | GSE73268 | GEO

Next Generation Sequencing Facilitates Quantitative Analysis of normal mice, colitis mice, normal mice receiving berberine and colitis mice receiving berberine colon transcriptomes

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of normal mice, colitis mice, normal mice receiving berberine and colitis mice receiving berberine colon transcriptomes

| PRJNA809930 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of DSS-induced colitis receiving Sulfasalazine and Berberine colonrectum Transcriptomes

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of DSS-induced colitis receiving Sulfasalazine and Berberine colonrectum Transcriptomes

| PRJNA892880 | ENA

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Project description:This is a single arm phase II study of adjuvant intra-dermal NA DC vaccine combined with intravenous nivolumab in patients with resectable HCC (group A) or CRLM (group B) planned for curative surgery (with/without local ablation).

| 2379524 | ecrin-mdr-crc

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

Project description:Immune checkpoint inhibitor-based combination therapy produced high objective response for patients with hepatocellular carcinoma (HCC) and may improve clinical outcome as neoadjuvant or peri-operative therapy. This study evaluated efficacy and safety of nivolumab plus ipilimumab for patients potentially resectable HCC and explored potential predictive biomarkers for efficacy.

2025-09-20 | GSE302495 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data